Related Experiment Video

Updated: Jul 5, 2025

DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

20.6K

Advancing cancer treatment: in vivo delivery of therapeutic small noncoding RNAs

Xiaoyue Yang1, Ying Liang2, Sheng Tong1

  • 1F. Joseph Halcomb III, MD Department of Biomedical Engineering, University of Kentucky, Lexington, KY, United States.

Frontiers in Molecular Biosciences
|January 18, 2024
PubMed

Insights

Small non-coding RNAs (ncRNAs) show promise as cancer therapeutics by targeting oncogenes. This review highlights clinical studies and delivery challenges for advancing ncRNA cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Small non-coding RNAs (ncRNAs) are emerging as potent regulators of genetic networks.
  • ncRNAs offer a novel therapeutic avenue in oncology, complementing traditional small-molecule drugs.
  • Advancements in ncRNA therapeutics necessitate efficient in vivo delivery strategies.

Purpose of the Study:

  • To review current clinical and preclinical studies on small ncRNA-based cancer therapeutics.
  • To identify key challenges, particularly delivery methods, hindering the clinical translation of ncRNA therapies.
  • To stimulate innovative approaches for effective ncRNA delivery in cancer treatment.

Main Methods:

  • Comprehensive literature review of clinical and preclinical studies.
  • Analysis of current research on small ncRNA-based cancer therapeutics.
  • Focus on delivery strategies and associated challenges.

Main Results:

  • Small ncRNAs demonstrate potential in modulating genetic networks and targeting oncogenes for cancer therapy.
  • Significant progress has been made in preclinical and clinical investigations of ncRNA therapeutics.
  • Delivery methods remain a critical bottleneck for successful clinical application.

Conclusions:

  • Small ncRNA therapeutics represent a promising frontier in cancer treatment.
  • Overcoming delivery challenges is crucial for the clinical success of ncRNA-based cancer therapies.
  • Further innovation in delivery systems is essential to realize the full potential of ncRNA therapeutics.
Keywords:
cancerin vivo deliverymiRNAsiRNAsmall non-coding RNA

More Related Videos

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.1K
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.4K

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K